Ayala is currently evaluating AL102 in our Phase 2/3 RINGSIDE trial for the treatment of patients with progressing desmoid tumors. Ayala is planning to initiate a Phase 2 trial of AL102 for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia (R/R T-ALL).
Ayala is also currently evaluating AL101 in a Phase 2 ACCURACY trial for the treatment of patients with recurrent/metastatic adenoid cystic carcinoma (R/M ACC).
As part of our commitment to advancing the treatment of rare tumors and aggressive cancers, we are conducting clinical trials of our investigational medicines to demonstrate their safety and efficacy in cancer patients. People who choose to participate in clinical trials play a critical role in developing new medicines.